ARS Pharmaceuticals Submits Response to FDA Letter for Neffy
By Chris Wack
ARS Pharmaceuticals has submitted its response to the U.S. Food and Drug Administration for its New Drug Application of neffy epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis.
The submission follows receipt of a Complete Response Letter from the FDA in September 2023, which identified two additional requests: completion of a repeat dose pharmacokinetic/pharmacodynamic study of neffy under nasal allergen challenge (NAC) conditions, and completion of updated nitrosamine testing per the FDA's draft guidance issued in August 2023.
In February 2024, ARS Pharma successfully completed the repeat dosing study of neffy in seasonal allergic rhinitis under NAC conditions. ARS Pharma also completed the nitrosamine testing requested with no measurable levels of nitrosamines detected.
The original neffy NDA was submitted in August 2022. In May 2023, the FDA Advisory Committee determined a favorable benefit-risk profile for neffy: 16:6 for adults and 17:5 for children. No committee member requested a repeat dose study during allergen-induced allergic rhinitis.
ARS Pharma sees an FDA review period of up to six months, and the PDUFA date is anticipated to be Oct. 2, 2024, based on the submission receipt date of April 2, 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 03, 2024 09:33 ET (13:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk